These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34177949)

  • 1. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
    Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
    Front Immunol; 2021; 12():690821. PubMed ID: 34177949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
    Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
    Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.
    Marinozzi MC; Roumenina LT; Chauvet S; Hertig A; Bertrand D; Olagne J; Frimat M; Ulinski T; Deschênes G; Burtey S; Delahousse M; Moulin B; Legendre C; Frémeaux-Bacchi V; Le Quintrec M
    J Am Soc Nephrol; 2017 May; 28(5):1603-1613. PubMed ID: 28096309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?
    Marinozzi MC; Vergoz L; Rybkine T; Ngo S; Bettoni S; Pashov A; Cayla M; Tabarin F; Jablonski M; Hue C; Smith RJ; Noris M; Halbwachs-Mecarelli L; Donadelli R; Fremeaux-Bacchi V; Roumenina LT
    J Am Soc Nephrol; 2014 Sep; 25(9):2053-65. PubMed ID: 24652797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
    Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
    J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
    Frimat M; Tabarin F; Dimitrov JD; Poitou C; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
    Blood; 2013 Jul; 122(2):282-92. PubMed ID: 23692858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.
    Ding Y; Zhao W; Zhang T; Qiang H; Lu J; Su X; Wen S; Xu F; Zhang M; Zhang H; Zeng C; Liu Z; Chen H
    Sci Rep; 2017 Jul; 7(1):6004. PubMed ID: 28729648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-factor B antibodies in atypical hemolytic uremic syndrome.
    Khandelwal P; Nambiar S; Saini R; Saini S; Coshic P; Sinha A; Hari P; Palanichamy JK; Bagga A
    Pediatr Nephrol; 2024 Jun; 39(6):1909-1916. PubMed ID: 38252289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?
    Noris M; Remuzzi G
    Kidney Int; 2020 Nov; 98(5):1084-1087. PubMed ID: 33126970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
    Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
    Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
    Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
    Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
    Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.
    Smith-Jackson K; Yang Y; Denton H; Pappworth IY; Cooke K; Barlow PN; Atkinson JP; Liszewski MK; Pickering MC; Kavanagh D; Cook HT; Marchbank KJ
    J Clin Invest; 2019 Mar; 129(3):1061-1075. PubMed ID: 30714990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.